Improving the management of ALK-rearranged non-small-cell lung cancer through a mobile application: a physicians-based survey.

ALK rearrangements account for around 5% of non-small-cell lung cancers. This study surveys physicians on the potential efficacy of a mobile application in improving the management of ALK-rearranged non-small-cell lung cancer, through knowledge, treatment adherence and real-time adverse events reporting. A total of 118 physicians from 11 countries in the Middle East participated.